Get alerts on this situation
We’ll email you as it develops, and you can follow the whole thread from day one.
Unsubscribe anytime.
[SITUATION] · [ACTIVE]
2 clusters · 2 sources · 21 days · First seen · Last updated
Categories: BUSINESS
AbbVie earnings and stock performance
Entities: Glenmede Trust Co. NA · AbbVie · Williams‑Sonoma, Inc. · Incyte Corporation · Apogee Therapeutics
Overview
In early July 2026 AbbVie’s shares slipped modestly even as analysts raised price targets, indicating a cautious market reaction despite optimistic forecasts. By the end of the month the company released its second‑quarter results, showing revenue just under $17 billion and a modest earnings beat, but it cut its full‑year adjusted EPS outlook and linked the downgrade to the pending Apogee Therapeutics acquisition. The guidance cut and concerns over the acquisition prompted a roughly 3 % decline in AbbVie’s stock price, contrasting with the earlier modest slip and highlighting heightened investor sensitivity to earnings guidance and strategic moves.
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Glenmede Trust Co. NA reduced its stake in Incyte by 4.7% during the first quarter, selling 25,715 shares. (Glenmede Trust Co. NA)
- [○ 1 SOURCE] After the sale, Glenmede owned about 0.26% of Incyte, valued at $49,252,000. (Glenmede Trust Co. NA)
- [○ 1 SOURCE] Glenmede Trust Co. NA reduced its stake in Williams‑Sonoma by 18.2% during the first quarter, selling 42,028 shares. (Glenmede Trust Co. NA)
- [○ 1 SOURCE] After the sale, Glenmede owned about 0.16% of Williams‑Sonoma, valued at $34,443,000. (Glenmede Trust Co. NA)
Timeline
-
3 days ago
[BUSINESS] 2 sourcesGlenmede Trust Co. NA Cuts Stakes in Incyte and Williams‑SonomaGlenmede Trust Co. NA sold 25,715 Incyte shares (down 4.7%) and 42,028 Williams‑Sonoma shares (down 18.2%) in Q1, leaving 0.26% and 0.16% stakes worth $49.3 M and $34.4 M respectively.
-
23 days ago
[BUSINESS] 2 sourcesAbbVie shares slip modestly as analysts lift price targetsAbbVie stock slipped ~1% as analysts raised price targets to $263‑$295 and investors, including Norges Bank, increased holdings.
Sources
mommygearest.com · stocknews.com